/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
MONTREAL, Oct. 24, 2013 /CNW Telbec/ - OPMEDIC GROUP INC. ("OPMEDIC
GROUP" or the "Corporation") (TSX: OMG), issue a reminder that a
Special Meeting of Shareholders will be held in the Offices of Norton
Rose Fulbright Canada LLP, 1 Place Ville Marie, Suite 2500, Montreal,
Quebec, H3B 1R1, on Friday, November 1, 2013, at 9:00 a.m. Eastern
The Special Meeting will consider resolutions set forth in the
Management Information Circular dated October 3, 2013 with respect to
the proposed amalgamation (the "Transaction") of the Corporation with
Kemourmedic Acquisition Inc., a corporation indirectly owned and
controlled by Drs. Pierre St-Michel, Marc Villeneuve and Jean-Yves
Registered shareholders are reminded that the cut-off time for
submitting proxies in order to vote on the Transaction is 5:00 p.m.,
Eastern time, on Wednesday, October 30, 2013. Beneficial shareholders
who hold their shares in brokerage or investment accounts or through
intermediaries may have an earlier cut-off date to submit their votes
through their voting instruction form.
A copy of the Management Information Circular, the form of proxy and
related documents are accessible on SEDAR at www.sedar.com. Registered shareholders who have questions should contact the
Corporation's registrar and transfer agent and the depositary for the
Transaction, Computershare Investor Services Inc., at tel.
1-800-564-6253, or by e-mail: firstname.lastname@example.org. Beneficial or non-registered shareholders should contact their broker,
dealer, custodian or other intermediary that administers the account in
which their shares are held.
About OPMEDIC GROUP
OPMEDIC GROUP is a company incorporated under the laws of the Province
of Quebec which provides healthcare-related services including surgical
and endoscopic facilities and services to patients and surgeons (with
its OPMEDIC division), fertility treatments, medical imaging,
laboratory services and diagnostic procedures (with its PROCREA
Cliniques division, its subsidiary 8362556 Canada Inc. and a joint
venture 7667264 Canada Inc.) and sperm banking services (with its
PROCREA Cryopreservation Centre subsidiary). OPMEDIC GROUP's Common
Shares trade on the TSX under the symbol "OMG".
This press release may contain certain "forward‐looking statements".
Forward‐looking statements are subject to certain risks and
uncertainties, many of which are beyond the Corporation's control.
There can be no assurance that such statements will prove to be
accurate. Consequently, actual results and future events may
differ materially from those anticipated by such statements. Readers
should not rely unduly on such forward‐ looking statements. The
risks and uncertainties include, but are not limited to, the
satisfaction of the conditions to consummate the Transaction, including
the approval of the Transaction by the shareholders, the
occurrence of any event, change or other circumstances that
could give rise to termination of the Transaction, a delay in the
consummation of the Transaction or failure to complete the Transaction
for any other reason, the amount of the costs, fees, expenses and
charges related to the Transaction, and the risks associated with
general economic conditions. The forward‐looking statements in
this press release are made as of the date of this press release and,
except as required by law, OPMEDIC GROUP disclaims any
obligation to update or revise publicly any forward‐looking
statements, whether as a result of new information or future events.
The content of this press release has not been approved by nor submitted
to the TSX which assumes no liability therefor.
SOURCE: OPMEDIC GROUP INC.
For further information:
Vice President Finance and Chief Financial Officer
(514) 345-8535, x 2260